More than half of large U.S. employers plan to scale back healthcare benefits next year as rising costs from weight-loss and ...

While some employers have covered GLP-1s hoping for long-term health savings, rising prices are forcing a rethink: "Some ...

People who take GLP-1 drugs like Ozempic can lose weight even if they face disruptions in accessing the medications, which ...

The luxury group's jewelry division, which houses heavyweight brands Cartier and Van Cleef & Arpels, saw an 11% rise in sales. The Jeep parent said it would discontinue its hydrogen fuel-cell ...

Growth in Richemont's jewelry division, which includes the Cartier brand, has buoyed group sales in recent quarters and offset declines at its specialist watchmakers business. The world's ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Novo Nordisk NVO shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and ...

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

The California Public Employees’ Retirement System (CalPERS) has a new pharmacy benefits contract with CVS Caremark, the ...

A new study says the health of American children has gotten worse across the board in the last 17 years. Published in the ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The ...